Diary No: 17031
Date: 11.07.2017

F. No 12-29/16-DC (Phase IV)
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
FDA Bhawan, New Delhi – 110002 (India)
New Drugs Division

Tele No.011-23236965
Fax.No.011-23236973

Dated: 16-07-2018

To,
M/s. Amgen Technology Private Limited,
Dynasty Business Park,
A wing Level 4, Andheri Kurla Road,
Maharashtra, India Mumbai 400059,

Subject: Phase IV study to evaluate safety, tolerability and efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma - regarding.

Reference: Application No. REG/2017/062 dated 06.12.2016.

CT NOC No. CT/ND/27/2018

Sir,

This Directorate has no objection to your conducting the subject mentioned clinical trial as per the provisions of Drugs & Cosmetics Rules under supervision of the following investigators and as per the **Protocol No: 20160372, Version No: Original, dated 09.06.2017** submitted to this Directorate.

Sr. No.	Investigator & Trial site	Ethics Committee Name/Registration Number
1.	**Dr. Vikram Mathews,** Department of Haematology, Christian Medical College, Vellore-632004, TN	Ethics committee Silver, Research office, first floor, Carman block, Christian Medical college, Vellore 632002,Tamil Nadu **ECR/326/Inst/TN/2013/RR-16**
2.	**Dr. Manju Sengar,** Department of Oncology, tata Memorial Hospital, Dr. Ernest Borges Marg, Parel, Mumbai-400012, India	The Chairperson Institutional Ethics Committee, Tata Memorial Hospital, Main building, 3rd floor, Parel, Mumbai Dr. Ernest Borges Road, Parel, Mumbai- 400012 **ECR/414/Inst/MH/2013/RR-16** **ECR/170/Inst/MH/2013/RR-16**
3.	**Dr. Rajnish Nagarkar,** Department of Oncology, Curie Manavata Cancer Centre, Nashik, Maharashtra-422004	Manavata Clinical Research Institute Ethics Committee situated at Curie Manavata Cancer Centre, Mumbai Naka,Nashik-422204 **ECR/500/Inst/MH/2013/RR-16**
4.	**Dr. Sadanand Karandikar,** Department of Oncology, Ruby Hall Clinic, 40 Sassoon Road, New Cancer Building Pune, Maharashtra-4110001	Poorna Medical Research Foundation E4-C to E4-F 4th Floor Fifth Venue Condominium Dhole Patil Road, Pune -411001 **ECR/24/Inst/MH/2013/RR-16**
5.	**Dr. Rajendra Kumar,** Department of Oncology, King Georges Medical University, Lucknow-226003	Institutional Ethics Committee at office of Research Cell Administrative block King George Medical University Lucknow-226003 **ECR/262/Inst/UP/2013/RR-16**

6.	**Dr. Prashanth Ganeshan,** Department of Medical Oncology, Cancer Institute (WIA), Sardar Patel Road, Chennai-600036	Cancer Institute WIA East Canal bank Road Gandhi Nagar Adyar Chennai Tamil nadu-600020 **ECR/235/Inst/TN/2013/RR-16**
7.	**Dr. Prantar Chakrabarti,** Department of Haematology, Institute of Haematology and transfusion Medicine, Kolkata, West Bengal-700014	Institutional Ethics Committee, Institute of Haematology and transfusion Medicine,3rd Floor, MCH building Medical College , 88 College Street, Kolkata West Bengal-700073. **ECR/609/Inst/WB/2014**
8.	**Dr. Mukul Goyal,** Department of Oncology, Apex Hospital Pvt. Ltd, Malviya Nagar, Jaipur, Rajasthan-303017	Apex Hospital private Limited ,Sp-4 &6, Malviya Industrial Area, Malviya Nagar, Jaipur-302017 **ECR/380/Inst/RJ/RR-2016**
9.	**Dr. Sandip Saha,** Department of Haematology, Vedanta Institute of Medical Science, Navrangpura, Ahmedabad, Gujrat-380009	Care Institute of medical sciences, NT shukan Mall Off Sciences City Road Ahmedaba, Gujrat-380009 **ECR/206/Inst/Guj/2013/RR-16**

Kindly note that the clinical trial permission is subject to the following Conditions:

a) Clinical trial shall be conducted in compliance with the approved protocols, requirements of Schedule Y, Good Clinical Practice Guidelines issued by this Directorate and other applicable regulations.

b) Approval of Institutional Ethics Committee duly registered with CDSCO (under Rule 122DD of Drugs & Cosmetics Rules) should be obtained and submitted to this Directorate before initiation of the study.

c) Clinical trials shall be registered at Clinical trials Registry of India before enrolling the first patient for the study.

d) Annual status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Licensing Authority, and in case of termination of any clinical trial the detailed reasons for the same shall be communicated to the said Licensing Authority.

e) Any report of serious adverse event occurring during clinical trial study to the subject, after due analysis, shall be forwarded within fourteen days of its occurrence as per Appendix XI and in compliance with the procedures prescribed in Schedule Y.

f) In case of an injury or death during the study to the subjects, the applicant shall provide complete medical management and compensation in the case of trial related injury or death in accordance with rule 122 DAB and the procedures prescribed under Schedule Y, and the details of compensation provided in such cases shall be intimated to the Licensing Authority within thirty days of the receipt of the order of the said authority.

g) The premises of Sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical trial study sites shall be open to inspection by the officers authorized by the Central Drugs Standard Control Organization, who may be accompanied by an officer of the State Drug Control Authority concerned, to verify compliance to the requirements of Schedule Y, Good Clinical Practices guidelines for conduct of clinical trial in India and other applicable regulations.

h) The Sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical trial study sites and the Investigator shall allow officers authorized by the Central Drugs Standard Control Organization, who may be accompanied by an officer of the State Drug Control Authority concerned, to enter with or without prior notice, any premises of Sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical trial sites to inspect, search and seize any record, data, document, books, Investigational drugs, etc. Related to clinical trial and provide adequate replies to any queries raised by the inspecting authority in relation to the conduct of clinical trial.

i) Clinical trial shall be conducted only at those sites which are institutes/hospitals having adequate emergency facilities and duly registered Institutional Ethics committees.

j) The sponsor shall ensure that the number of clinical trials an investigator can undertake should be commensurate with the nature of the trial, facility available with the Investigator etc. However, under no circumstances the number of trials to be conducted by an Investigator should be more than three at a time.

k) The details of payment/honorarium/financial support/fees paid by the Sponsor to the Investigator(s) for conducting the study shall be made available to this directorate before initiation of each of the trial sites.

l) In addition to the requirement of obtaining written informed consent, an audio-video recording of the informed consent process in case of vulnerable subjects in clinical trial of New Chemical Entity or New Molecular Entity including procedure of providing information to the subject and his understanding on such consent, shall be maintained by the investigator for record; provided that in case of clinical trial of anti-HIV and anti leprosy drugs, only audio recording of the informed consent process of individual subject including the procedure of providing information to the subject and his understanding on such consent shall be maintained by the investigator for record, as per Government of India, Gazette Notification vide G. S. R. no. 611(E) dated 31.07.2015.

m) The formulation intended to be used in the clinical trial shall be manufactured under GMP conditions using validated procedures and shall have ongoing stability programme.

n) The firm should complete the study and submit the report within 4 years. Additionally, the firm should submit interim report of study within 2 years.

Yours faithfully,



(Dr. S. Eswara Reddy)
Drugs Controller General (India)